VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Stocks in this Quantisnow insightHealth Care
Historical context for VIVS
Across the 14 sessions after earlier VIVS headlines, the stock closed higher 4 times and lower 9 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VIVS | SPY |
|---|---|---|---|
| Oct 7, 2026 | VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods | -5.2% | -0.2% |
| Sep 16, 2026 | VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | -3.8% | -0.4% |
| Sep 1, 2026 | VivoSim Labs to Add Rat Liver Model to NAMkind Platform | -4.4% | -0.7% |
| Aug 6, 2026 | VivoSim Provides Financial and Listing Compliance Update | -9.2% | -0.2% |
| Jul 21, 2026 | VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services | -10.9% | +0.8% |
| Jul 16, 2026 | VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor | -28.1% | -0.5% |
Keep researching VIVS
Quantisnow market dataNASDAQ
VIVS
VivoSim Labs Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for VIVS
Full VIVS profile on Quantisnow Follow VIVS and get a push notification the moment its next story breaks.